Emily L. Rapalino

Emily L. Rapalino is a highly experienced patent litigation attorney, specializing in complex intellectual property disputes within the life sciences sector. Her practice focuses on pharmaceutical and biotechnology patent litigation, particularly Hatch-Waxman and biosimilar litigation. She draws on advanced degrees in biology to navigate the scientific and technical complexities inherent in these cases.

Rapalino primarily represents defendants in patent disputes, with her tracked appearances reflecting two defendant-side roles. Her experience includes securing victories for generic and biosimilar manufacturers, such as Teva in Eloxatin® patent disputes and Sandoz in the Esbriet® patent dispute. She is a partner at Goodwin Procter, having previously been an associate at Fish & Neave.

Her notable cases include representing defendants in the significant Regeneron Pharmaceuticals Inc. v. Mylan Pharmaceuticals Inc. and Regeneron Pharmaceuticals, Inc. v. Sandoz Inc. biosimilar patent litigations concerning aflibercept (Eylea®). While Regeneron initially secured a permanent injunction against Mylan, the case ultimately concluded with a stipulated dismissal and settlement in April 2025. The Sandoz case also settled, allowing Sandoz to launch its biosimilar product in late 2026. She also played a key role in a trial win for Cephalon involving the oncology drug Treanda®.

Rapalino possesses experience with proceedings before the Patent Trial & Appeal Board (PTAB), having been a featured speaker on navigating the differences between PTAB proceedings and district court litigation. She earned her J.D. from Columbia Law School in 2002, an M.Sc. in Life Sciences from the Weizmann Institute of Science, and an A.B. in Biology, cum laude, from Harvard University. She has been admitted to practice since 2003.